The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process

Circulation. 2005 Apr 5;111(13):1697-702. doi: 10.1161/01.CIR.0000161370.77463.0F.
No abstract available

Publication types

  • Consensus Development Conference
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Cardiovascular Agents / adverse effects
  • Cardiovascular Agents / standards*
  • Clinical Trials as Topic
  • Drug Approval*
  • Humans
  • Long QT Syndrome / chemically induced
  • Risk Assessment
  • United States
  • United States Food and Drug Administration*

Substances

  • Cardiovascular Agents